3-(4-甲氧基苄基)哌啶 | 136422-65-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(4-甲氧基苄基)哌啶
• 英文名称: 3-(4-methoxyphenylmethyl)piperidine
• 英文别名: 3-(4-methoxybenzyl)-piperidine；3-(4-methoxybenzyl)piperidine；3-[(4-methoxyphenyl)methyl]piperidine
• CAS: 136422-65-6
• 化学式: C₁₃H₁₉NO
• mdl: MFCD05863592
• 分子量: 205.3
• InChiKey: MEMNAZVIXVXAJS-UHFFFAOYSA-N

物化性质

• 沸点：
  315.0±15.0 °C(Predicted)
• 密度：
  1.002±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-(4-甲氧基苄基)哌啶 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 3.0h， 生成 (4-chlorophenyl)-carbamic acid (S)-2,2,2-trifluoro-1-[3-(4-methoxybenzyl)-piperidin-1-ylmethyl]-ethyl ester
  参考文献：
  名称：

  [EN] SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS
  [FR] COMPOSÉS CARBAMATE SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU CANAL POTENTIEL RÉCEPTEUR TRANSITOIRE (TRP)

  摘要：

  该发明涉及式(I)的化合物及其药学上可接受的盐，其中Y、R1和R3在详细描述和权利要求中有定义。此外，本发明涉及制备和使用式(I)的化合物的方法，以及含有这些化合物的药物组合物。式(I)的化合物是TRPA1通道的拮抗剂，可能对治疗与该通道相关的炎症性疾病和紊乱有用。

  公开号：

  WO2014060341A1
• 作为产物：
  描述：

  (4-甲氧基苯基)(吡啶-3-基)甲醇 在 palladium on activated charcoal 氢气 、 溶剂黄146 作用下， 70.0 ℃ 、800.0 kPa 条件下， 生成 3-(4-甲氧基苄基)哌啶
  参考文献：
  名称：

  轻松合成3-（取代的苄基）哌啶

  摘要：

  通过将取代的苯基溴化镁加到吡啶-3-甲醛中，然后在钯催化剂的存在下进行一锅脱氧和杂芳族环饱和，已经开发了一种方便的新方法来制备一系列3-（取代的苄基）哌啶。

  DOI：

  10.1016/j.tet.2003.08.023

文献信息

• Selective NR1/2B <i>N</i>-Methyl-<scp>d</scp>-aspartate Receptor Antagonists among Indole-2-carboxamides and Benzimidazole-2-carboxamides
  作者：István Borza、Éva Bozó、Gizella Barta-Szalai、Csilla Kiss、Gábor Tárkányi、Ádám Demeter、Tamás Gáti、Viktor Háda、Sándor Kolok、Anikó Gere、László Fodor、József Nagy、Kornél Galgóczy、Ildikó Magdó、Béla Ágai、József Fetter、Ferenc Bertha、György M. Keserü、Csilla Horváth、Sándor Farkas、István Greiner、György Domány

  DOI：10.1021/jm060420k

  日期：2007.3.1

  (4-Benzylpiperidine-1-yl)-(6-hydroxy-1H-indole-2-yl)-methanone (6a) derived from (E)-1-(4-benzylpiperidin-1-yl)-3-(4-hydroxy-phenyl)-propenone (5) was identified as a potent NR2B subunit-selective antagonist of the NMDA receptor. To establish the structure-activity relationship (SAR) and to attempt the improvement of the ADME properties of the lead, a series of compounds were prepared and tested. Several derivatives showed low nanomolar activity both in the binding and in the functional assay. In a formalin-induced hyperalgesia model in mice, 6a and (4-benzylpiperidine-1-yl)-[5(6)-hydroxy-1H-benzimidazol-2-yl]-methanone (60a) were as active as besonprodil (2) after oral administration. A CoMSIA model was developed based on binding data of a series of indole- and benzimidazole-2-carboxamides.

  (4-苄基哌啶-1-基)-(6-羟基-1H-吲哚-2-基)-甲酮(6a)是从(E)-1-(4-苄基哌啶-1-基)-3-(4-羟基苯基)丙烯酮(5)中鉴定出的一种强效的NMDA受体NR2B亚基选择性拮抗剂。为了建立结构-活性关系(SAR)并尝试改善先导化合物的ADME性质，制备并测试了一系列化合物。多种衍生物在结合和功能性测定中均显示出低纳摩尔的活性。在环磷酰胺诱导的小鼠痛觉过敏模型中，6a和(4-苄基哌啶-1-基)-[5(6)-羟基-1H-联吡啶-2-基]-甲酮(60a)在口服给药后与Besonprodil(2)具有相同的活性。基于一系列吲哚-和联吡啶-2-羧酰胺的结合数据，开发了一种CoMSIA模型。
• [EN] AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS<br/>[FR] DERIVES AMIDIQUES COMME ANTAGONISTES DU RECEPTEUR NMDA
  申请人：RICHTER GEDEON VEGYESZET

  公开号：WO2002034718A1

  公开（公告）日：2002-05-02

  The invention relates to new NR2B selective NMDA receptor antagonist carboxylic acid amide derivatives of formula (I) as well as the recemates, optical antipodes and the salts thereof formed with acids and bases. Fruthermore objets of the present invention are the pharmaceutical compositions containing compounds of formula (I) or the salts thereof as active ingredients, as well as the synthesis of compounds of formula (I), and the chemical and pharmaceutical manufacture of medicaments containing these compounds, as well as the method of treatments with these compounds, which means administering to a mammal to be treated - including human - effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament. The new carboxylic acid amide derivatives of formula (I) of the present invention are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.

  本发明涉及公式（I）的新型NR2B选择性NMDA受体拮抗剂羧酸酰胺衍生物，以及与酸和碱形成的外消旋体，光学对映体和其盐。此外，本发明的目标是含有公式（I）化合物或其盐作为活性成分的制药组合物，以及公式（I）化合物的合成，以及含有这些化合物的药物的化学和制药制造，以及使用这些化合物的治疗方法，即向待治疗的哺乳动物（包括人类）施用本发明的化合物的有效量/量，作为药物或单独使用。本发明的新型羧酸酰胺衍生物的公式（I）是高效和选择性的NMDA受体拮抗剂，而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。
• Inhibitors of Ion Channels
  申请人：Marron Brian Edward

  公开号：US20130072471A1

  公开（公告）日：2013-03-21

  Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.

  本发明提供了在通过抑制电压门控钠通道中的钠离子流来治疗疾病方面有用的化合物、组合物和方法。更具体地，本发明提供了取代芳基磺酰胺、包含这些化合物的组合物，以及使用这些化合物或组合物治疗中枢或外周神经系统疾病，特别是疼痛和慢性疼痛的方法，通过阻断与所示条件的发生或复发相关的钠通道来实现。本发明的化合物、组合物和方法特别适用于通过抑制电压门控钠通道中的离子流来治疗神经病性或炎症性疼痛。
• SUBSTITUTED CARBAMATE COMPOUNDS
  申请人：HOFFMANN-LA ROCHE INC

  公开号：US20150218141A1

  公开（公告）日：2015-08-06

  The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

  本发明涉及式(I)的化合物及其药学上可接受的盐，其中Y、R1和R3在详细说明和权利要求中有定义。此外，本发明还涉及制造和使用式(I)化合物的方法，以及含有这些化合物的制药组合物。式(I)化合物是TRPA1通道的拮抗剂，可能有助于治疗与该通道相关的炎症性疾病和障碍。
• INHIBITORS OF ION CHANNELS
  申请人：Marron Brian Edward

  公开号：US20090143358A1

  公开（公告）日：2009-06-04

  Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.

  本发明提供了化合物、组合物和方法，通过抑制电压门控钠通道中的钠离子流来治疗疾病。更具体地，本发明提供了取代芳基磺酰胺、包含这些化合物的组合物，以及使用这些化合物或组合物治疗中枢或外周神经系统疾病，特别是疼痛和慢性疼痛的方法，通过阻止与所示疾病的发生或复发有关的钠通道。本发明的化合物、组合物和方法特别适用于通过抑制电压门控钠通道中的离子流来治疗神经病理性或炎症性疼痛。